Cargando…
A proof-of-principle study of epigenetic therapy with hydralazine and magnesium valproate plus doxorubicin cyclophosphamide as neoadjuvant therapy for locally advanced breast cancer
Autores principales: | Arce, Claudia, Perez-Plasencia, Carlos, Gonzalez-Fierro, Aurora, de la Cruz-Hernandez, Erik, Revilla-Vazquez, Alma, Chavez-Blanco, Alma, Trejo-Becerril, Catalina, Perez-Cardenas, Enrique, Taja-Chayeb, Lucia, Bargallo, Enrique, Villarreal, Patricia, Ramirez, Teresa, Vela, Teresa, Candelaria, Myrna, Camargo, Maria F, Robles, Elizabeth, Dueñas-Gonzalez, Alfonso |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1796567/ http://dx.doi.org/10.1186/1471-2407-7-S1-A23 |
Ejemplares similares
-
Epigenetic therapy with hydralazine and valproate associated to cisplatin chemoradiation in FIGO stage IIIB. A phase II study
por: Candelaria, Myrna, et al.
Publicado: (2007) -
A Proof-Of-Principle Study of Epigenetic Therapy Added to Neoadjuvant Doxorubicin Cyclophosphamide for Locally Advanced Breast Cancer
por: Arce, Claudia, et al.
Publicado: (2006) -
A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors
por: Candelaria, Myrna, et al.
Publicado: (2007) -
Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines
por: Chavez-Blanco, Alma, et al.
Publicado: (2006) -
DNA Methylation-Independent Reversion of Gemcitabine Resistance by Hydralazine in Cervical Cancer Cells
por: Candelaria, Myrna, et al.
Publicado: (2012)